Lubrizol integrates personal, home and health care divisions16 Jul 2019
The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.
The Lubrizol Corporation has reorganized its personal, home and health care business lines, integrating them under a newly dedicated brand, Lubrizol Life Science.
The change reflects the company's commitment to evolve with the beauty, health, home and wellness markets, which continue to cross over and converge. The newly formed Lubrizol Life Science team seeks to enhance the value of its solutions and services to customers and end users through its collective expertise in chemistry, applications and market insights.
"Lubrizol Life Science brings together a great variety of formulation and product development experience to sit under one umbrella," says Lubrizol Advanced Materials President Rick Tolin. "Our internal capabilities are focused and aligned to help our customers quickly meet the expectations of today's consumers for products that ensure them of a healthier, more beautiful and comfortable life."
The newly aligned Lubrizol Life Science team is placing a priority on developing and testing products in partnership with customers, engineering breakthroughs and co-driving initiatives that fuel growth. Practices and processes emphasize agile innovation, enabling the organization to act at the speed of a start-up, while responding with the reach, resources and delivery of a global leader. The new brand will also emphasize the proactive innovation needed to bring market-ready solutions to customers, while capitalizing on the reliability of Lubrizol's 90 years of science and efficacy.
Tolin points out: "Our beauty, health and home customers can count on us bringing truly differentiated products to market, formulated with ingredients that are consumer-driven and backed by the reliability of Lubrizol." Tolin adds, "The Lubrizol Life Science team is poised to service customers throughout the value chain, from concept to commercialization. Once viewed by customers as a chemical and ingredient supplier, we have evolved into an essential, concept-to-commercialization solutions partner."
Lubrizol Life Science also plans to add strategic technology, capability and talent by investing to expand its portfolio, including new acquisitions that bring unique opportunities and synergies.
CPhI and AAPS partner to expand expert scientific content at CPhI North America
10 Jan 2020
CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...Read more
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API
9 Jan 2020
The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.Read more
New HQ for developer of world's first fully automated drug discovery platform
8 Jan 2020
End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.Read more
Catalent completes purchase of biologics fill-finish and oral solid dose facility
7 Jan 2020
Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.Read more
Boxing clever: Smart packs improving communication with patients
6 Jan 2020
Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.Read more
WuXi STA opens large-scale oligonucleotide manufacturing facility
6 Jan 2020
Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.Read more
NIH researchers discover new autoinflammatory disease
3 Jan 2020
Mutations in the RIPK1 gene responsible for CRIA syndrome.Read more
UCB to build new biotech manufacturing plant in Belgium
31 Dec 2019
Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.Read more
BioAscent scientists help identify potential new treatments for cancer
30 Dec 2019
Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.Read more
Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences
27 Dec 2019
Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation